先进急诊医学

IL-6/IL-6R 拮抗剂治疗类风湿关节炎的研究进展

李 绚容

右江民族医学院

张 渝

右江民族医学院附属医院

陶 丽菊

右江民族医学院附属医院

DOI: https://doi.org/10.59429/xjjz.v6i4.8636

Keywords: 类风湿关节炎；IL-6；IL-6 拮抗剂；IL-6 受体拮抗剂

---

Abstract

类风湿关节炎（Rheumatoid Arthritis，RA）是一种常见的自身免疫性疾病，其主要特征是滑膜增生和血管 翳形成，其发病原理和机制尚未完全清楚，目前认为 IL-6（Interleukin-6）为 RA 发生途径中的重要细胞因子，在 RA 患者的关节损伤、系统破坏和与 RA 有关并发症中产生重要作用。而 IL-6/IL-6R（Interleukin-6 receptor）拮抗剂作为 新型改善病情抗风湿药物（Disease-Modifying anti-rheumatic drugs，DMARDs），可阻断 IL-6 信号通路，可改善对传 统抗风湿药（csDMARDs）反应不佳的患者带来获益。现已有多种 IL-6/IL-6R 拮抗剂在临床上使用，或目前正在研 发之中。这些药物已被证实在 RA 治疗中具有很好的疗效及安全性。论文对 IL-6 在 RA 的作用机制及 IL-6/IL-6R 拮 抗剂治疗的相关进展进行综述，为临床诊疗提供参考。

---

References

[1] Kobayashi Y, Kobayashi H, Giles J T, et al. Association of tocilizumab treatment with changes in measures of regional left ventricular function in rheumatoid arthritis, as assessed by cardiac magnetic resonance imaging[J]. Int J Rheum Dis,2016,19(11):1169-1174.

[2] McInnes I B, Schett G. The pathogenesis of rheumatoid arthritis[J]. N Engl J Med,2011,365(23):2205-2219.

[3] 聂明明.类风湿关节炎患者的血清IL-6水平以及与骨质疏松的相关性[J].中国现代医生,2021,59(3):77-80.

[4] Damoiseaux J. The IL-2 - IL-2 receptor pathway in health and disease: The role of the soluble IL-2 receptor[J]. Clin Immunol, 2020(218):108515.

[5] 孟静楠,赵韵琦,张伦军,等.类风湿关节炎患者外周血25羟基维生素D、白介素-6的表达[J].中国临床研究,2022,35(2):190-193.

[6] 李岩异,张卫婷.IL-6:TNF-α之后的类风湿关节炎治疗关键靶点[J].生物工程学报,2017,33(1):36-43.

[7] 范星宇,洪梦琴,杨敏.IL-6与类风湿关节炎的关系及作用机制的研究进展[J].世界最新医学信息文摘,2019,19(86):65-69.

[8] 刘昱廷,曾令伟,王柠柠.托珠单抗联合塞来昔布对中重度类风湿关节炎患者炎症反应的影响研究[J].中国处方药,2023,21(7):103-106.

[9] 苏哲,张宁.托珠单抗治疗中重度类风湿关节炎的临床研究[J].实用药物与临床,2019,22(5):526-529.

[10] 黄煜鹏,刘钢.托珠单抗治疗难治性类风湿关节炎的疗效与安全性[J].华西医学,2017,32(7):988-992.

[11] 张敏,谭震,马艳,等.托珠单抗联合cDMARDs治疗难治性类风湿关节炎的疗效及安全性评估[J].中华疾病控制杂志,2018,22(2):211-214.

[12] Kang S, Tanaka T, Narazaki M, et al. Targeting Interleukin-6 Signaling in Clinic[J]. Immunity,2019,50(4):1007-1023.

[13] 王圣.托珠单抗治疗类风湿关节炎的疗效及安全性评价[D].济南:山东大学,2020.

[14] 汪达青,朱珈漩,王芳,等.托珠单抗联合MTX治疗类风湿关节炎患者细胞免疫指标变化特点[J].临床检验杂志,2023,41(02):132-135.

[15] 杜勤,徐红娣.托珠单抗对类风湿关节炎患者疗效、免疫球蛋白及辅助性T细胞水平的影响[J].药学实践杂志,2020,38(1):71-73.

[16] Kondo N, Fujisawa J, Endo N. Subcutaneous Tocilizumab Is Effective for Treatment of Elderly-Onset Rheumatoid Arthritis[J]. Tohoku J Exp Med,2020,251(1):9-18.

[17] Specker C, Aringer M, Burmester G R, et al. The safety and effectiveness of tocilizumab in elderly patients with rheumatoid arthritis and in patients with comorbidities associated with age[J]. Clin Exp Rheumatol,2022,40(9):1657-1665.

[18] 张建忠.2017年5月FDA批准新药概况[J].上海医药,2017,38(13):79-80.

[19] Genovese M C, Fleischmann R, Kivitz A J, et al. Sarilumab Plus Methotrexate in Patients With Active Rheumatoid Arthritis and Inadequate Response to Methotrexate: Results of a Phase III Study[J]. Arthritis Rheumatol,2015,67(6):1424-1437.

[20] Burmester G R, Lin Y, Patel R, et al. Efficacy and safety of sarilumab monotherapy versus adalimumab monotherapy for the treatment of patients with active rheumatoid arthritis (MONARCH): a randomised, double-blind, parallel-group phase III trial[J]. Ann Rheum Dis,2017,76(5):840-847.

[21] Genovese M C, Fleischmann R, Kivitz A J, et al. Sarilumab Plus Methotrexate in Patients With Active Rheumatoid Arthritis and Inadequate Response to Methotrexate: Results of a Phase III Study[J]. Arthritis Rheumatol,2015,67(6):1424-1437.

[22] Fleischmann R, van Adelsberg J, Lin Y, et al. Sarilumab and Nonbiologic Disease-Modifying Antirheumatic Drugs in Patients With Active Rheumatoid Arthritis and Inadequate Response or Intolerance to Tumor Necrosis Factor Inhibitors[J]. Arthritis Rheumatol,2017,69(2):277-290.

[23] 纪英博,闫荟羽,张杰,等.Sarilumab治疗类风湿关节炎进展[J].中南药学,2018,16(10):1400-1403.

[24] 赵俊轶,宁红,唐瑜莹,等.IL-6抑制剂Sirukumab治疗类风湿关节炎疗效和安全性的meta分析[J].中国现代应用药学,2020,37(1):60-68.

[25] Aletaha D, Bingham C R, Tanaka Y, et al. Efficacy and safety of sirukumab in patients with active rheumatoid arthritis refractory to anti-TNF therapy (SIRROUND-T): a randomised, double-blind, placebo-controlled, parallel-group, multinational, phase 3 study[J]. Lancet,2017,389(10075):1206-1217.

[26] Takeuchi T, Yamanaka H, Harigai M, et al. Sirukumab in rheumatoid arthritis refractory to sulfasalazine or methotrexate: a randomized phase 3 safety and efficacy study in Japanese patients[J]. Arthritis Res Ther,2018,20(1):42.

[27] Tanaka Y, Takeuchi T, Harigai M, et al. Efficacy and safety of sirukumab in Japanese patients with active rheumatoid arthritis who were refractory or intolerant to anti-tumor necrosis factor therapy: Subgroup analysis of a randomized, doubleblind, multicenter, phase 3 study (SIRROUND-T)[J]. Mod Rheumatol,2019,29(2):306-313.

[28] Ho L Y, Gyu S G. Comparison of the efficacy and safety of tocilizumab, sarilumab, and olokizumab in patients with active rheumatoid arthritis: a network meta-analysis of randomized controlled trials[J]. Z Rheumatol, 2024,83(1):97-106.

[29] Abuelazm M, Ghanem A, Mahmoud A, et al. The efficacy and safety of olokizumab for rheumatoid arthritis: a systematic review, pairwise, and network meta-analysis[J]. Clin Rheumatol, 2023,42(6):1503-1520.

[30] Feist E, Fleischmann R M, Fatenejad S, et al. Olokizumab plus methotrexate: safety and efficacy over 106 weeks of treatment[J]. Ann Rheum Dis,2024.

[31] Smolen J S, Feist E, Fatenejad S, et al. Olokizumab versus Placebo or Adalimumab in Rheumatoid Arthritis[J]. N Engl J Med, 2022,387(8):715-726.

[32] Lee Y H, Song G G. Comparison of the efficacy and safety of olokizumab at different dosages in patients with active rheumatoid arthritis: a network meta-analysis of randomized controlled trials[J]. Z Rheumatol, 2024,83(1):107-114.

[33] Lisitsyna T A, Abramkin A A, Veltishchev D Y, et al. Efficacy of Olokizumab against Comorbid Depressive Disorder in Patients with Rheumatoid Arthritis: Preliminary Results of the Study[J]. Dokl Biochem Biophys, 2024,517(1):195-206.